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Abstract Interleukin-21 (IL-21) has recently been identi¢ed as
a novel 4-helix-bundle type I cytokine possessing a cytokine
receptor Q chain essential for the immune response. We report
the preparation and functional characterization of Escherichia
coli-expressed recombinant human IL-21 (rIL-21). The rIL-21,
expressed as insoluble inclusion bodies in E. coli, was solubilized
and then refolded by using a modi¢ed dialysis method. The
introduction of redox reagents during refolding led to a dramat-
ic increase in the refolding e⁄ciency. Circular dichroism spec-
trum analysis showed that the refolded rIL-21 had an K-helix as
a secondary structure, which is a characteristic of type I cyto-
kines. Flow cytometry con¢rmed previous reports that rIL-21
binds to CD3-activated T cells (T-LAK) and to cell lines Raji,
HL60, and Jurkat. rIL-21 stimulated the proliferation of
T-LAK but not peripheral blood mononuclear cells, and this
e¡ect seems to be identical to that of co-stimulation with anti-
CD3 antibody. Growth inhibition assay indicated that enhance-
ment of the cytotoxicity of T-LAK to the human bile duct
carcinoma TFK-1 depended on the concentration of rIL-21.
Thus, refolded rIL-21 had activity identical to that of authentic
IL-21 and enhanced the anti-tumor activity of T-LAK. These
conclusions suggest the potential use of the refolded cytokine in
adoptive immunotherapy using T-LAK cells and in the discovery
of other functions of the cytokine. 5 2002 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Interleukin-21 (IL-21) was identi¢ed in 2000 [1]. It belongs
to the type I cytokine family and has homology to IL-2, IL-4,
and IL-15. Its receptor, IL-21R, has marked sequence homol-
ogy to the Q chain of IL-2R. IL-21 has a role in the prolifer-
ation and maturation of natural killer cells from bone mar-
row, in the proliferation of mature B cells under co-
stimulation with anti-CD40 monoclonal antibody (mAb),
and in the proliferation of T cells under co-stimulation with
anti-CD3 mAb [1]. It shares a common cytokine receptor
Q chain, which is essential for the immune response, with
IL-2, IL-4, IL-7, IL-9, and IL-15 [2]. Although the Q chain
is dispensable for the binding of IL-21 to IL-21R, it is essen-
tial for the signaling by IL-21R of the activation of Janus
kinase (JAK) 1 and JAK3, followed by phosphorylation of
STAT1 and STAT3 [2]. These facts indicate that the Q chain is
an indispensable subunit of IL-21R, as seen in IL-2 signaling
via IL-2R binding. Because IL-21 signaling has not been func-
tionally characterized, a highly e⁄cient system for preparing
IL-21 would be useful to researchers in immunology and med-
icine. In addition, the cytokine may be useful for adoptive
immunotherapy through its use in activating T cells.
Recent advances in genetic engineering have made it easier
to prepare recombinant proteins such as cytokines, chemo-
kines, co-stimulatory molecules, and fragments of variable
regions of antibodies (Fv) [3^6]. The successful construction
of several proteins by using bacterial expression systems has
been reported, and some proteins are now used for therapeu-
tic purposes [7^9]. Overproduction of proteins, however, often
leads to the formation of insoluble aggregates, referred to as
inclusion bodies, in the cytoplasmic or periplasmic space. In
many cases, the inclusion bodies are made of the expressed
proteins. If these proteins can be refolded, large quantities can
be made available for industrial and therapeutic needs [10,11].
Therefore, a stable and convenient refolding system would
bene¢t the preparation of recombinant proteins.
Here, we describe the successful construction of recombi-
nant human IL-21 (rIL-21) from Escherichia coli inclusion
bodies comprising highly expressed proteins that were re-
folded into the functional form by stepwise dialysis. rIL-21
may prove useful in adoptive immunotherapy using T-LAK
cells and in the investigation of novel functions and e¡ects of
IL-21.
2. Materials and methods
2.1. Construction of rIL-21 expression vector
A completely synthesized gene for rIL-21 was made from six oligo-
nucleotides by using an overlap-extension polymerase chain reaction
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(PCR) method as described previously [12,13]. In brief, the oligonu-
cleotides were approximately 90 bp in length and had overlapping
regions of about 20 bp (Table 1). These oligonucleotides were de-
signed using codons that exist with high frequency in the E. coli
genome (Table 1). The six oligonucleotides were assembled, and the
full-length DNA was ampli¢ed by PCR (Fig. 1). A 2nd PCR used two
external primers and the DNA fragments ampli¢ed by the 1st PCR as
templates. The ¢nal PCR product was digested with NcoI and SacII
and cloned into a T7 promoter-based pUT vector [10].
2.2. Expression and puri¢cation of rIL-21
rIL-21 was expressed and puri¢ed as described previously [14]. In
brief, E. coli strain BL21 (DE3) transformed with rIL-21 expression
vector was incubated at 37‡C in LB broth. When the optical density
reached 0.8 at 600 nm, 1 mM isopropyl-1-thio-L-D-galactopyranoside
was added to the culture to induce protein production, and the cells
were grown overnight. Cell pellets separated from the culture by
centrifugation (2000g, 35 min) were resuspended in 10 ml phos-
phate-bu¡ered saline (PBS), ultrasonicated at 150 W for 15 min,
and centrifuged at 4500g for 20 min. Then the separated intracellular
insoluble fraction was solubilized and denatured with 10 ml of 6 M
guanidine-HCl in PBS overnight at 4‡C. After solubilization, the pro-
teins were puri¢ed in a Talon metal a⁄nity resin column (Clontech,
Palo Alto, CA, USA).
2.3. Refolding of rIL-21 by stepwise dialysis
We have previously shown the preparation system of functional
soluble antibody fragments from this insoluble aggregate using the
stepwise dialysis in vitro refolding system [15]. Thus, here we used a
modi¢ed method to obtain functional rIL-21 from the intracellular
insoluble fraction. Puri¢ed rIL-21 was diluted to 7.5 WM with 6 M
guanidine-HCl in 50 mM Tris^HCl (pH 8.0), and stepwise dialysis
was used to remove the denaturant as previously reported [15]. To
obtain soluble rIL-21, we optimized the refolding system of a previous
report [10]. The refolding procedure is summarized in Fig. 2. To
increase the refolding e⁄ciency, we added 3.75 mM reducing reagent
(reduced form of glutathione; Sigma, St. Louis, MO, USA) and 375
WM oxidizing reagent (oxidized form of glutathione; Sigma) to the
refolding solution when the concentration of guanidine-HCl was 1 and
0.5 M for shu¥ing the disul¢de bonds.
2.4. Gel ¢ltration
Gel ¢ltration of refolded rIL-21 was performed using a Superdex 75
column (Amersham Biosciences, Little Chalfont, Buckinghamshire,
UK) (2.6U60 cm) connected to an FPLC system pre-equilibrated
with PBS. 10 ml of refolded protein was subjected to gel ¢ltration
at a £ow rate of 3.0 ml/min.
2.5. SDS^PAGE and Western blotting
The analysis used 500-Wl aliquots of culture supernatant. The total
protein in each fraction, precipitated with 6% trichloroacetic acid and
0.083% deoxycholate, was submitted to sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE) under reducing condi-
tions as previously reported [16] and stained with Coomassie brilliant
blue R-250. Then the proteins in the gel were blotted onto nitrocellu-
lose membranes (Amersham) and incubated with peroxidase-conju-
gated anti-His tagged mAb (Invitrogen). The ECL Detection System
(Amersham) was used for signal enhancement.
2.6. Circular dichroism (CD) spectrum measurement
CD spectra were measured with an AVIV Circular Dichroism Spec-
trometer with a 0.1-cm quartz cuvette for the near-UV spectrum and a
1-cm quartz cuvette for the far-UV spectrum. The conditions were
1-nm band width, 4-s averaging time, and four scans.
2.7. Preparation and stimulation of e¡ector cells
For induction of T-LAK cells, peripheral blood mononuclear cells
(PBMCs) donated by a healthy volunteer and isolated by density-
gradient centrifugation were cultured for 48 h in RPMI-1640 medium
supplemented with 10% fetal bovine serum, 100 U/ml penicillin,
100 Wg/ml streptomycin and 100 IU/ml recombinant human IL-2
(kindly supplied by Shionogi Pharmaceutical, Osaka, Japan) at a
cell density of 1U106/ml in a culture £ask (A/S Nunc, Roskilde, Den-
mark) pre-coated with OKT3 mAb (mouse IgG2a) (10 Wg/ml). The
induced T-LAK cells were then transferred to another £ask and ex-
panded in culture medium containing 100 IU/ml recombinant human
IL-2 for 2^3 weeks [17].
2.8. Flow cytometric analysis
Test cells (5U105) were incubated for 30 min on ice with 100 Wl
rIL21 (about 100 Wg/ml). After washing in PBS plus 0.1% NaN3, they
were exposed to 9E10 anti-c-myc mAb (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and then £uorescein isothiocyanate (FITC)-
conjugated anti-mouse IgG, both for 30 min on ice. The stained cells
were analyzed by £ow cytometry (FACS Calibur; Becton Dickinson,
San Jose¤, CA, USA).
2.9. Proliferation assay of PBMCs and T-LAK cells
Proliferation of mitogen-activated human PBMCs and T-LAK cells
was assessed by using a Cell Proliferation enzyme-linked immunoas-
say (ELISA) system (Amersham). Brie£y, 1U105 freshly isolated
PBMCs suspended in 0.2 ml culture medium were added to each
well of 96-well £at-bottomed plates (Sumitomo Bakelite, Osaka, Ja-
pan) in the presence of various concentrations (from 0.1 to 100 ng/ml)
of rIL-21. After incubation for 48 h at 37‡C, 5-bromo-2P-deoxyuridine
(BrdU) labeling reagent was added, and the cells were incubated for
an additional 24 h. Cell labeling was detected according to the man-
ufacturer’s assay protocol for cells in suspension. The optical density
was measured by using a plate reader (model 3550; Bio-Rad, Tokyo,
Japan) at 450 nm.
2.10. In vitro growth inhibition assay
The enhanced anti-tumor e¡ects of the constructed rIL-21 were
evaluated in a growth inhibition assay using various cell lines (i.e.
human bile duct carcinoma TFK-1, human lung carcinoma OBA-
LK1 and human colon cancer DLD-1) as a target and T-LAK cells
or PBMCs as an e¡ector. In vitro growth inhibition assays were
performed with a 3-(4,5-dimethylthiazole-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay kit
(CellTiter 96; aqueous, non-radioactive cell proliferation assay;
Promega, Madison, WI, USA). Target cells (5000 cells in 100 Wl cul-
ture medium) were added to 48 wells of a 96-well £at-bottomed plate
(Costar, Cambridge, MA, USA). The cells were cultured overnight to
allow adhesion to the bottom of the wells. After removal of the cul-
ture medium by aspiration, 100 Wl of T-LAK cells or PBMCs plus
various concentrations (from 1.25 to 10 ng/ml) of rIL-21, or 100 Wl of
rIL-21 alone, was added to each well. After culture for 48 h at 37‡C,
Table 1
Primers of overlap-extension PCR for whole synthesized IL-21 gene
1st PCR primers
(1) 5P-NNNCCATGGCCCAGGATCGCCATATGATTCGCATGCGTCAGCTGATTGATATTGTTGATCAGCTGAAAAACTATGTGAACGACTTGGTGC-3P
(2) 5P-GAGCGCCTTTAGCTGCTTtCAGAAAGCGCAGCTGAAATCTGCGAATACCGGCAACAATCAACGCATCATTAATGTGAGCATTA-3P
(3) 5P-CAGAAACATCGTCTGACCTGCCCGTCATGTGATTCTTATGAAAAAAAGCCGCCGAAAGAATTTCTGGAACGTTTCAAATCTCTT-3P
(4) 5P-AAAGCAGCTAAAGGCGTCCATTCACAGTTGGTTTCCACATCTTCCGGGGCCGGCAGAAATTCCGGCACCAAGTCGTTCACATA-3P
(5) 5P-AGGTCAGACGATGTTTCTGGCGACGACCGGCATTGGTAGACGGCGGTTTACGTTTCAGCTTTTTAATGCTCACATTAATGATGCG-3P
(6) 5P-NNNCCGCGGCCGCAGAATCTTCACTGCCGTGGGTGCGAGAGCTCAGATGCTGGTGGATCATTTTTTGCAGAAGAGATTTGAAACGTTCCAGA-3P
2nd PCR primers
reverse primer 5P-NNNCCATGGCCCAGGATCGCCATA-3P
forward primer 5P-NNNCCGCGGCCGCAGAATCTTCA-3P
Numbering of 1st PCR primers correspond to Fig. 1. The italic letters of each primers show restriction enzyme sites and underlined letters indi-
cate overlap regions.
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each well was washed three times with PBS to remove e¡ector cells
and dead target cells. This step was followed by the addition of 95 Wl/
well of culture medium and 5 Wl/well of a fresh mixture of MTS/
phenazine methosulfate solution (Promega). The plates were incuba-
ted for 1 h at 37‡C and then read on a microplate reader (Bio-Rad
model 3550) at 490 nm. Growth inhibition of target cells was calcu-
lated as follows: % growth inhibition= [13(A490 of experiment3A490
of background)/(A490 of control3A490 of background)] U100 [18].
3. Results
3.1. Expression of recombinant IL-21 as inclusion body in
E. coli
Recombinant IL-21 (rIL-21) was expressed in E. coli strain
BL21 (DE3). SDS^PAGE and Western blotting using anti-
His-tagged Ab showed that rIL-21 existed mainly in the intra-
cellular insoluble fraction (Fig. 3a, b).
3.2. Puri¢cation and refolding of rIL-21
SDS^PAGE analysis revealed highly puri¢ed rIL-21 as a
single band with an estimated size of 18.4 kDa (Fig. 3c).
The refolding e⁄ciency was about 57% with oxidizing reagent
alone but 90% with oxidizing and reducing reagents. This
result suggests the critical role of the shu¥ing of disul¢de
bonds during refolding. Gel ¢ltration analysis indicated the
monomeric structure of the refolded protein (Fig. 4). The
refolded rIL-21 did not aggregate even after incubation at
37‡C for a week (data not shown). Thus, the folding was
stable. The ¢nal yield of refolded IL-21 was s 200 mg/l of
culture.
3.3. CD spectrum measurement
The troughs at 208 and 222 nm in the far-UV spectrum
(Fig. 5a) show that rIL-21 has an K-helix-rich secondary
structure. This result corresponds well with the previous pre-
diction that IL-21 has a 4-helix-bundle structure because of its
primary amino acid sequence and the characteristic structure
of a type I cytokine [1]. The near-UV spectrum (Fig. 5b)
suggested the interaction of an aromatic residue in the tertiary
structure of the protein. These results show that the rIL-21
prepared by disul¢de shu¥ing was refolded and contains an
K-helix as a secondary structure.
3.4. Flow cytometric analysis
The binding activity of rIL-21 to IL-21R was con¢rmed by
£ow cytometry using IL-21R-positive cell lines and lympho-
kine-activated T cells (T-LAK cells). Refolded rIL-21 bound
Fig. 1. Construction of genes encoding IL-21 by overlap-extension
PCR. See details in text.
Fig. 2. Procedure for refolding E. coli-expressed recombinant IL-21.
See details in Materials and Methods. The bu¡er solution during re-
folding is 50 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA (pH 8.0,
4‡C). Each dialysis step lasts 6^12 h. The concentration of reducing
reagent added for disul¢de shu¥ing is shown in parentheses. GSSH,
oxidized form of glutathione; GSH, reduced form of glutathione;
L-Arg; L-arginine.
Fig. 3. Expression and puri¢cation of recombinant IL-21. (a) SDS^
PAGE under reducing conditions and (b) Western blot analysis by
anti-His-tagged mAb of fractions of E. coli BL21 (DE3) cells ex-
pressing rIL-21. Lane 1, proteins in the bacterial supernatant frac-
tion; 2, proteins in the intracellular soluble fraction; 3, proteins in
the intracellular insoluble fraction (inclusion bodies). (c) SDS^
PAGE under reducing conditions of fractions separated by immobi-
lized metal a⁄nity chromatography under denaturing conditions.
Lane 4, total proteins in the insoluble fraction; 5, £ow-through
fraction; 6, wash fraction; 7, eluted fraction.
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to IL-21R-positive cells, Raji cells (human Burkitt lympho-
ma), HL-60 cells (human blood promyelocytic leukemia),
and Jurkat cells (human T cell leukemia) (Fig. 6a). It also
bound to T-LAK cells (Fig. 6b), but bound very little to
PBMCs (Fig. 6c). IL-21 co-stimulated anti-CD3-activated thy-
mocytes and mature T cells [1]. Thus, our results show that
IL-21R was also expressed on T-LAK cells stimulated by
CD3. This suggests that the refolded rIL-21 may be suitable
as an enhanced molecule in adoptive immunotherapy using
T-LAK cells. The binding activity of the refolded protein
was retained even after incubation for 1 week at 37‡C (data
not shown).
3.5. Proliferation assay of PBMCs and T-LAK cells
The rIL-21 did not induce the proliferation of PBMCs at
any dose from 0.1 to 100 ng/ml (Fig. 7). On the other hand, it
e¡ectively stimulated the proliferation of T-LAK cells at doses
from 1 to 100 ng/ml (Fig. 7). There was no remarkable di¡er-
ence in the concentration of the rIL-21 over the range (data
not shown). These results reveal that rIL-21 has a signi¢cant
e¡ect on the proliferation of T-LAK cells.
3.6. Growth inhibition assay of TFK-1 cells mediated by
T-LAK cells and PBMCs
rIL-21 strongly enhanced the inhibition by T-LAK of TFK-
1 cells at e¡ector:target (E:T) ratios of 5:1 and 10:1 (Fig. 8).
No enhanced cytotoxic e¡ect was found when PBMCs were
used as e¡ector cells and when only rIL-21 was used without
e¡ector cells (data not shown). The e¡ect of rIL-21 on TFK-1
cells was saturated at nanogram concentrations.
3.7. rIL-21-mediated enhanced cytotoxicity against other cell
lines
We assayed the inhibition by rIL-21 of two other cell lines:
OBA-LK1 and DLD-1. The rIL-21 gave the same inhibition
of both cell lines as it did of TFK-1 cells, although the sensi-
tivity for the T-LAK cells was di¡erent (Fig. 9a, b).
4. Discussion
Interleukin-21 is a recently discovered IL-2-like cytokine
that upregulates T cells under CD3 stimulation [1,2]. Here
we report large-scale preparation of E. coli-expressed rIL-21
in a high-yield refolding process. The yield of the protein
using conventional refolding method (i.e. dilution) has been
less than 50% (data not shown). On the other hand, the yield
of recombinant IL-21 refolded from insoluble inclusion bodies
overexpressed in E. coli was s 200 mg/L. The His-tagged rIL-
21 has a refolding e⁄ciency, physical stability, and biological
activity identical to the rIL-21 without the His-tag (data not
shown) and, thus, here we report the refolding and functional
characterization of His-tagged rIL-21.
If rIL-21 is a type I cytokine as has been proposed [1], two
disul¢de bonds should exist. Disul¢de bond formation is a
critical step in the correct folding of proteins. We have re-
cently reported a high-yield refolding process of single-chain
antibody Fv fragments and other proteins with immunoglob-
ulin folds [10]. Our method, however, gave a relatively low
e⁄ciency of rIL-21 refolding of 57%. The use of disul¢de
Fig. 4. Gel ¢ltration of refolded rIL-21. (a) Pro¢le of gel ¢ltration.
Refolded rIL-21 was subjected to gel ¢ltration on Superdex-75
(Amersham) (2.6U60 cm) connected to an FPLC system, pre-equili-
brated with PBS. 10 ml of refolded rIL-21 adjusted to 0.2 mg/ml
was subjected to gel ¢ltration at a £ow rate of 3 ml/min. (b) SDS^
PAGE of the eluted fraction.
Fig. 5. Circular dichroism spectra of refolded rIL-21 from disul¢de-
shu¥ing system in the region of 200^250 nm (a) and 250^320 nm
(b).
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shu¥ing increased the refolding e⁄ciency to 90%, indicating
that refolding e⁄ciency depends on protein folding and espe-
cially on the condition of the intramolecular disul¢de bonds.
The binding activity of the refolded protein was maintained
and no aggregation was observed even after incubation for
1 week at 37‡C (data not shown), suggesting the stable folding
of the rIL-21. Surprisingly, the protein could be successfully
refolded even at a relatively high concentration (V20 WM;
data not shown) with a high yield (V80%), suggesting that
the correct formation of disul¢de bonds at the appropriate
refolding stage may be critical for refolding the protein with
high yield. Note that the dialysis method developed for refold-
ing of immunoglobulin-like proteins can be used for K-helical
proteins if some parameters (e.g. concentration of redox solu-
tion) are correctly adjusted.
Some cytokines, for instance IL-2, IL-4, and IL-6, have
been expressed in E. coli and prepared from insoluble inclu-
sion bodies by refolding. In each case the proteins were func-
tional and identical to ones puri¢ed from mammalian cells
[19^22]. In addition, refolding increased the ¢nal yield by
more than 100 times the yield of the soluble fraction (e.g.
periplasmic fraction) in E. coli [11]. However, a relatively
low refolding e⁄ciency, such as that of IL-6, which consists
of 4-helix bundles with 2-disul¢de bonds, is sometimes a prob-
lem, especially in large-scale preparation for therapeutic uses
[23]. Therefore, our method could improve the preparation of
cytokines in an E. coli expression system.
IL-2 has been used as a modulator in adoptive immuno-
therapy in many studies. However, its strong side e¡ects have
limited its use [24^26]. Our results show that rIL-21 has no
e¡ect on the proliferation of PBMCs and the cytotoxicity for
tumor cell line using PBMCs (as a substitute of the e¡ector
cell for T-LAK cells) and using only rIL-21 without e¡ector
cells. This result provides strong support for the previous
suggestion that IL-21 is a co-stimulatory molecule [1]. When
injected into the bloodstream, fewer side e¡ects might be ex-
pected than from IL-2. IL-21 promotes antigen-speci¢c T cell
activation [27]. In addition, as we found, the refolded protein
seems to be stable under long-term incubation at 37‡C. There-
fore, human IL-21 may be a potent candidate as a co-stim-
ulator.
In conclusion, E. coli-expressed human rIL-21 can be re-
Fig. 6. Flow cytometry analysis of rIL-21 in (a) cell lines, (b) T-LAK cells, and (c) PBMCs. Shaded areas: cells incubated with rIL-21. After
incubation, mouse anti-c-myc mAb 9E10 was added, followed by staining with FITC-conjugated goat anti-mouse IgG. Unshaded areas: cells
incubated without rIL-21.
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folded with high yield by using a disul¢de-shu¥ing dialysis
method. The prepared protein could recognize IL-21R-posi-
tive cell lines and was e¡ective at promoting the proliferation
of T-LAK cells. Growth inhibition assay showed that en-
hanced T-LAK killer activity against human bile duct carci-
noma depended on concentration, indicating that IL-21 en-
hances cytotoxicity. Our recombinant IL-21 may help
researchers discover new functions and e¡ects of the cytokine.
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